Aurinia Pharmaceuticals
AUPH
13 hedge funds and large institutions have $33.2M invested in Aurinia Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
18% more funds holding
Funds holding: 11 → 13 (+2)
8% more capital invested
Capital invested by funds: $30.7M → $33.2M (+$2.58M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$1.7M |
| 2 |
Millennium Management
New York
|
+$571K |
| 3 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$365K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$603 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$3.84M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.16M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$64.1K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$46K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.61K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NMC
1
NEA Management Company
Timonium,
Maryland
| $11.1M | – | – | – |
|
|
GPP
2
Great Point Partners
Greenwich,
Connecticut
| $8.51M | -$2.16M | -544,432 | -22% |
|
|
RCM
3
RA Capital Management
Boston,
Massachusetts
| $6.56M | -$3.84M | -969,300 | -39% |
|
|
BBA
4
Baker Bros. Advisors
New York
| $3.12M | -$64.1K | -16,170 | -2% |
|
|
ACP
5
Acuta Capital Partners
Redwood City,
California
| $1.88M | +$1.7M | +430,000 | New |
|
|
6
Millennium Management
New York
| $628K | +$571K | +144,061 | New |
|
7
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $581K | – | – | – |
|
|
LOAMU
8
Lombard Odier Asset Management (USA)
New York
| $402K | +$365K | +92,088 | New |
|
|
CCMU
9
Cheyne Capital Management (UK)
London,
United Kingdom
| $401K | – | – | – |
|
|
10
Royal Bank of Canada
Toronto,
Ontario, Canada
| $48K | -$1.61K | -405 | -4% |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| $18K | +$603 | +152 | +5% |
|
|
12
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$46K | -12,500 | Closed |
|
13
Citigroup
New York
| – | -$519 | -131 | -77% |
|
AUPH Hedge Fund Activity: Q1 2015 in Review
13 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q1 2015, worth a combined $33.2M — up 8.4% from $30.7M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new AUPH positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 5 trimmed.
The largest buyer was Acuta Capital Partners, opening a new position worth an estimated $1.7M. The largest seller was RA Capital Management, cutting an estimated $3.84M.
- 13 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q1 2015, up from 11 in Q4 2014.
- Funds reported $33.2M of Aurinia Pharmaceuticals stock for Q1 2015, up 8.4% quarter-over-quarter.
- 3 funds opened new Aurinia Pharmaceuticals positions in Q1 2015 and 1 closed out, a net change of +2 holders.
- The largest Aurinia Pharmaceuticals buyer in Q1 2015 was Acuta Capital Partners, an estimated $1.7M added.
- The largest Aurinia Pharmaceuticals seller in Q1 2015 was RA Capital Management, an estimated $3.84M sold.
Based on aggregated 13F filings for Q1 2015.